Ouyang Xie

139 Renmin Rd
Changsha, 410011, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China.

Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China.

Journal: Future oncology (London, England)

Published: May 10, 2025

Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis.

Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: January 09, 2025

Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma.

Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: August 31, 2024

Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study.

Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study.

Journal: Clinical and molecular hepatology

Published: August 13, 2024

Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.

Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.

Journal: Frontiers in immunology

Published: July 13, 2024

Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis.

Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis.

Journal: Clinical rheumatology

Published: June 25, 2024

Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study.

Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study.

Journal: PharmacoEconomics

Published: June 24, 2024

Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.

Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.

Journal: Frontiers in pharmacology

Published: February 05, 2024

Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study.

Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study.

Journal: BMC medicine

Published: March 18, 2023

Showing 1-9 of 9

Last Updated: 09/26/2026